EvaluatePharma® delivers unique insight into the past and future performance of companies
in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service.
EvaluatePharma® provides a seamless set of financial and product information for pharmaceutical
and biotechnology companies with a combination of actual product sales and consensus sales forecasts,
to support informed commercial and investment decisions.
The complete product portfolios of more than 880 pharmaceutical and biotechnology companies are
covered, giving a universe of more than 21,000 products, from early stage R&D (research project), through
pre-clinical, phase I, phase II, phase III and filed classifications, and on to marketed (marketed,
approved, disposed and withdrawn) products. EvaluatePharma® also tracks
products that have been suspended or abandoned in R&D, including the time frame and phase
of development for each project.
Click on one of the company names to see a small sample of the data available relating to that company's
product portfolio and related news headlines, and to see an expanded description of the
data set available in EvaluatePharma® . To find out how you can access more detailed information covered by EvaluatePharma®
Contact Us today.
|
